New tissue imaging tool designed to revolutionize clinical research SOUTH SAN FRANCISCO, Calif. , April 17, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the launch of its
SOUTH SAN FRANCISCO, Calif. , March 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted an equity award effective as of March 20, 2023, under
Experienced Life Science Operating Leader Joins Board as Company Enters New Phase SOUTH SAN FRANCISCO, Calif. , March 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the
SOUTH SAN FRANCISCO, Calif. , March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm , PhD, will participate in a
SOUTH SAN FRANCISCO, Calif. , March 01, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm , PhD, will present at the Cowen
SOUTH SAN FRANCISCO, Calif. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 20, 2023 , under the
Fourth quarter 2022 GAAP revenues of $27.0 million ; Core product and service revenues of $26.8 million , representing 8.3% sequential growth; Full year GAAP revenues of $97.9 million and core product and service revenues of $94.5 million Improved operating discipline and restructuring initiatives
SOUTH SAN FRANCISCO, Calif. , Jan. 31, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report fourth quarter and full year 2022 financial results on Tuesday,
Continued commercial and strategic execution delivers sequential core revenue growth of 4% – 9% to $26 million – $27 million in Q4 2022 for full year total of approximately $94 million – $95 million Business restructuring and SBS program on track to deliver over 20% reduction in operating
Former Danaher Executive Further Strengthens Senior Management Team SOUTH SAN FRANCISCO, Calif. , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced the appointment of
